What is Genotox Laboratories?
Genotox Laboratories operates at the intersection of advanced toxicology and pharmacogenetic diagnostics. The company provides a critical service to healthcare providers through its DNA-verified urine drug testing and comprehensive pharmacogenetic assessments. Central to its value proposition is the ToxProtect system, a sophisticated mechanism designed to ensure sample integrity and bolster patient compliance. By integrating genetic insights into medication management, Genotox enables clinicians to develop highly personalized treatment protocols, effectively mitigating risks associated with opioid misuse and optimizing therapeutic outcomes. As a CLIA-certified entity, the organization maintains rigorous standards, ensuring that its diagnostic outputs remain a cornerstone for patient-centric care in complex clinical environments.
How much funding has Genotox Laboratories raised?
Genotox Laboratories has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1M led by PPP
Key Investors in Genotox Laboratories
PPP
Public-Private Partnership
What's next for Genotox Laboratories?
With the recent influx of capital, Genotox Laboratories is expected to scale its diagnostic capabilities and expand its market reach within the enterprise healthcare sector. The strategic focus will likely shift toward enhancing the scalability of the ToxProtect platform and deepening its integration with electronic health record systems to streamline clinical workflows. As the demand for precision-based medication monitoring continues to rise, the company is well-positioned to leverage its current financial stability to pursue further technological advancements in pharmacogenetic screening, ultimately solidifying its status as a leader in the diagnostic laboratory space.
See full Genotox Laboratories company page
